title: Cetuximab Might Be Detrimental to Metastatic Colorectal Cancer Patients with KRAS Codon 12 Mutations.
abstract: BACKGROUND
  Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies benefit patients with wild-type KRAS exon 2 metastatic colorectal cancer (mCRC). However, their effect in KRAS-mutant mCRC remains unclear.
  
  
  METHODS
  This was a retrospective study enrolling 163 patients with unresectable KRAS-mutant mCRC diagnosed at the National Taiwan University Hospital between 2007 and 2011.
  
  
  RESULTS
  The median overall survival (mOS) was 29.5 months in patients who had never used cetuximab and 19.0 months in those who had (p=0.040). The mOS was 32.0 months in patients with mutant KRAS codon 12 who had never used cetuximab and 17.5 months in those who had (p=0.017). In patients with mutant KRAS codon 13, the mOS was not significantly different. Univariate and multivariate Cox proportional hazards analysis revealed that absence of cetuximab treatment was an independent prognostic factor for longer mOS in patients with unresectable KRAS-mutant mCRC.
  
  
  CONCLUSIONS
  Cetuximab usage might be detrimental to patients with mCRC with mutant KRAS codon 12.
authors.affiliation: Department of Oncology, National Taiwan University, Hsin-Chu Branch, Hsinchu, Taiwan, R.O.C. Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan, R.O.C.
authors.forename: Yi-Hsin
authors.initials: YH
authors.lastname: Liang
authors.affiliation: Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan, R.O.C. Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan, R.O.C.
authors.forename: Yu-Lin
authors.initials: YL
authors.lastname: Lin
authors.affiliation: Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan, R.O.C.
authors.forename: Jau-Yu
authors.initials: JY
authors.lastname: Liau
authors.affiliation: Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan, R.O.C.
authors.forename: Jia-Huei
authors.initials: JH
authors.lastname: Tsai
authors.affiliation: Division of Colorectal Surgery, National Taiwan University Hospital, Taipei, Taiwan, R.O.C. Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan, R.O.C.
authors.forename: Jin-Tung
authors.initials: JT
authors.lastname: Liang
authors.affiliation: Division of Colorectal Surgery, National Taiwan University Hospital, Taipei, Taiwan, R.O.C. Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan, R.O.C.
authors.forename: Been-Ren
authors.initials: BR
authors.lastname: Lin
authors.affiliation: Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan, R.O.C.
authors.forename: Ji-Shiang
authors.initials: JS
authors.lastname: Hung
authors.affiliation: Department of Medical Genetics, National Taiwan University Hospital, Taipei, Taiwan, R.O.C.
authors.forename: Li-Hui
authors.initials: LH
authors.lastname: Tseng
authors.affiliation: Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan, R.O.C. Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei, Taiwan, R.O.C.
authors.forename: Liang-In
authors.initials: LI
authors.lastname: Lin
authors.affiliation: Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan, R.O.C. Graduate Institute of Pathology, College of Medicine, National Taiwan University, Taipei, Taiwan, R.O.C.
authors.forename: Yih-Leong
authors.initials: YL
authors.lastname: Chang
authors.affiliation: Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan, R.O.C. Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, R.O.C. Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan, R.O.C.
authors.forename: Ann-Lii
authors.initials: AL
authors.lastname: Cheng
authors.affiliation: Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan, R.O.C. Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan, R.O.C. Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan, R.O.C. khyeh@ntu.edu.tw.
authors.forename: Kun-Huei
authors.initials: KH
authors.lastname: Yeh
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000068818:Cetuximab; D003062:Codon / Q000235:genetics*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000235:genetics; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009154:Mutation / Q000235:genetics*; D009362:Neoplasm Metastasis / Q000235:genetics*; D011379:Prognosis; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D016283:Proto-Oncogene Proteins p21(ras); D012189:Retrospective Studies; D013624:Taiwan; D055815:Young Adult; D018631:ras Proteins / Q000235:genetics*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D003062:Codon; C117307:KRAS protein, human; D011518:Proto-Oncogene Proteins; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins; D000068818:Cetuximab
keywords: Cetuximab; KRAS; epidermal growth factor receptor; metastatic colorectal cancer